A polymorphism in the cyclooxygenase 2 gene in type 1 diabetic patients with nephropathy

Physiological Research

Volumn 60, Issue 2, 2011, Pages 377-380

  Hubacek J A ^a   Pelikanova T ^a   Lanska V ^a   Komers, R ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

765G>C polymorphism; Cyclooxygenase 2; Diabetic nephropathy

Indexed keywords

EID: 79959209302     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: 10.33549/physiolres.932016     Document Type: Article

References (9)

1. CHERNEY DZ, MILLER JA, SCHOLEY JW, BRADLEY TJ, SLORACH C, CURTIS JR, DEKKER MG, NASRALLAH R, HEBERT RL, SOCHETT EB: The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes 57: 688-695, 2008.
2. CIPOLLONE F, TONIATO E, MARTINOTTI S, FAZIA M, IEZZI A, CUCCURULLO C, PINI B, URSI S, VITULLO G, AVERNA M, ARCA M, MONTALI A, CAMPAGNA F, UCCHINO S, SPIGONARDO F, TADDEI S, VIRDIS A, CIABATTONI G, NOTARBARTOLO A, CUCCURULLO F, MEZZETTI A: A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 291: 2221-2228, 2004.
3. FURUKADO S, SAKAGUCHI M, YAMAGAMI H, YAGITA Y, HOSHI T, ABE Y, HOUGAKU H, HORI M, SAKODA S, KITAGAWA K: Cyclo-oxygenase-2 -765G> C promoter variants are associated with lower carotid plaque echogenicity in Japanese. Cerebrovasc Dis 27: 91-98, 2009.
4. KOMERS R, ANDERSON A, EPSTEIN M: Renal and Cardiovascular Effects of Selective Cyclooxygenase-2 Inhibitors. Am J Kidney Dis 38: 1145-1157, 2001.
5. LINTON MF, FAZIO S: Cyclooxygenase-2 and atherosclerosis. Curr Opin Lipidol 13: 497-504, 2002.
6. MILLER SA, DYKES DD, POLESKY HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215, 1988.
7. PAPAFILI A, HILL MR, BRULL DJ, MCANULTY RJ, MARSHALL RP, HUMPHRIES SE, LAURENT GJ: Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22: 1631-1636, 2002.
8. SMITH WL: The eicosanoids and their biochemical mechanisms of action. Biochem J 259: 315-324, 1989.
9. UTIMURA R, FUJIHARA CK, MATTAR AL, MALHEIROS DM, NORONHA IL, ZATZ R: Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 63: 209-216, 2003.